Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.
There has been tremendous insight gained in the last two decades from basic science research. New molecular targets in neoplastic cells are emerging and provide the rationale for clinical development of novel agents in non-Hodgkin lymphoma. These novel agents can be broadly categorized into two groups. The first is by immunotherapy which includes novel monoclonal antibodies and immunomodulating drugs, which takes advantage of or optimizes immune system function. The other group of drugs target small molecules that may play an important role in tumorigenesis. The mechanisms of anti-tumor activity include targeting apoptotic pathways, inhibition of proteasomes, mammalian target of rapamycin (mTOR), cyclin-dependent kinases and histone deacetylases. The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in non-Hodgkin lymphoma.
Tay
Kevin
K
Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Centre Drive, Bethesda, MD 20892-1203, USA.
Dunleavy
Kieron
K
Wilson
Wyndham H
WH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D016503:Drug Delivery Systems; D006801:Humans; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000970:Antineoplastic Agents